Effect of Chronic Exposure to Nextida GC-B on Glycemic Control in Adults With Normoglycemia or Prediabetes

Sponsor
Rousselot BVBA
Study ID
NCT07149064
Status
Recruiting
Apply to this trial

Conditions

  • Glycemic Control
  • Normoglycemia
  • Prediabetes

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Nextida GC-B — DIETARY_SUPPLEMENT
    One liquid shot contains 5 g of collagen hydrolysate.
  • Placebo — OTHER
    One liquid shot contains non-active ingredients in Nextida GC-B (water, Erythritol, Citric Acid, DL-Malic Acid, Natural Apples Flavor, Steviol Glycosides).

Study Details

The goal of this clinical trial is to investigate the safety and efficacy of Nextida GC-B on glycemic control in adults with normoglycemia and prediabetes. The main question it aims to answer is: What is the difference in change in postprandial glycemic control from baseline at Day 90 between Nextida GC-B and placebo as assessed by glucose incremental AUC (iAUC 0-180 min).

Key Dates

First listed
Aug 29, 2025
Start date
Feb 18, 2026
Status verified
Mar 2026
Primary completion
Aug 31, 2026
Completion
Aug 31, 2026

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Nextida GC-B
    This group receives one liquid shot of 5 g Nextida GC-B approximately 30 minutes before their two main meals (breakfast and lunch or breakfast and dinner) daily.
  • Placebo Comparator: Placebo
    This group receives one liquid shot of placebo approximately 30 minutes before their two main meals (breakfast and lunch or breakfast and dinner) daily.

Primary Outcome Measure

The difference in change in postprandial glycemic control between Nextida GC-B and placebo [ Time Frame: Day 0 to 90 ]

Central Contacts

Related Studies